Abstract
Metabolic dysregulation constitutes a pivotal feature of cancer progression. Enzymes with multiple metal active sites play a major role in this process. Here we report the first metabolic-enzyme-like FeMoO4 nanocatalyst, dubbed ‘artificial metabzyme’. It showcases dual active centres, namely, Fe2+ and tetrahedral Mo4+, that mirror the characteristic architecture of the archetypal metabolic enzyme xanthine oxidoreductase. Employing spatially dynamic metabolomics in conjunction with the assessments of tumour-associated metabolites, we demonstrate that FeMoO4 metabzyme catalyses the metabolic conversion of tumour-abundant xanthine into uric acid. Subsequent metabolic adjustments orchestrate crosstalk with immune cells, suggesting a potential therapeutic pathway for cancer. Our study introduces an innovative paradigm in cancer therapy, where tumour cells are metabolically reprogrammed to autonomously modulate and directly interface with immune cells through the intervention of an artificial metabzyme, for tumour-cell-specific metabolic therapy.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Data availability
The metallic structure models of MoO3, FeMoO4 and Fe3O4 are available at the Materials Project Database (https://materialsproject.org; mp-18856, mp-505526 and mp-19306). The structure model of XOR metabolic enzyme is available at the RCSB Protein Databank (https://rcsb.org; PDB 1FIQ). AFADESI-MSI imaging data have been deposited in the Metaspace database, enabling the visualization of MS imaging results. All the MS imaging data can be directly downloaded from https://metaspace2020.eu/project/metabzyme2024. Source data are provided with this paper.
Code availability
DFT calculations were conducted with Quantum Espresso, which is an open-source package and available at https://www.quantum-espresso.org/.
References
Elia, I. & Haigis, M. C. Metabolites and the tumour microenvironment: from cellular mechanisms to systemic metabolism. Nat. Metab. 3, 21–32 (2021).
Zaghlool, S. B. et al. Metabolic and proteomic signatures of type 2 diabetes subtypes in an Arab population. Nat. Commun. 13, 7121 (2022).
Faubert, B., Solmonson, A. & DeBerardinis, R. J. Metabolic reprogramming and cancer progression. Science 368, eaaw5473 (2020).
Patel, C. H., Leone, R. D., Horton, M. R. & Powell, J. D. Targeting metabolism to regulate immune responses in autoimmunity and cancer. Nat. Rev. Drug Discov. 18, 669–688 (2019).
Stine, Z. E., Schug, Z. T., Salvino, J. M. & Dang, C. V. Targeting cancer metabolism in the era of precision oncology. Nat. Rev. Drug Discov. 21, 141–162 (2022).
Goga, A. & Stoffel, M. Therapeutic RNA-silencing oligonucleotides in metabolic diseases. Nat. Rev. Drug Discov. 21, 417–439 (2022).
Tandon, S., Sharma, A., Singh, S., Sharma, S. & Sarma, S. J. Therapeutic enzymes: discoveries, production and applications. J. Drug Deliv. Sci. Technol. 63, 102455 (2021).
Martínez-Reyes, I. & Chandel, N. S. Cancer metabolism: looking forward. Nat. Rev. Cancer 21, 669–680 (2021).
Huang, C. et al. Hydrogen-bonded organic framework-based bioorthogonal catalysis prevents drug metabolic inactivation. Nat. Catal. 6, 729–739 (2023).
Huang, Y., Ren, J. & Qu, X. Nanozymes: classification, catalytic mechanisms, activity regulation, and applications. Chem. Rev. 119, 4357–4412 (2019).
Gao, W. et al. Deciphering the catalytic mechanism of superoxide dismutase activity of carbon dot nanozyme. Nat. Commun. 14, 160 (2023).
Zhang, R., Fan, K. & Yan, X. Nanozymes: created by learning from nature. Sci. China Life Sci. 63, 1183–1200 (2020).
Ji, S. et al. Matching the kinetics of natural enzymes with a single-atom iron nanozyme. Nat. Catal. 4, 407–417 (2021).
Yang, W. et al. Nanozymes: activity origin, catalytic mechanism, and biological application. Coord. Chem. Rev. 448, 214170 (2021).
Lee, B.-H. et al. Reversible and cooperative photoactivation of single-atom Cu/TiO2 photocatalysts. Nat. Mater. 18, 620–626 (2019).
Yang, J. et al. Modulating the strong metal-support interaction of single-atom catalysts via vicinal structure decoration. Nat. Commun. 13, 4244 (2022).
Metz, S. & Thiel, W. Theoretical studies on the reactivity of molybdenum enzymes. Coord. Chem. Rev. 255, 1085–1103 (2011).
Sun, Q. et al. Loss of xanthine oxidoreductase potentiates propagation of hepatocellular carcinoma stem cells. Hepatology 71, 2033–2049 (2020).
Monji, F., Al-Mahmood Siddiquee, A. & Hashemian, F. Can pentoxifylline and similar xanthine derivatives find a niche in COVID-19 therapeutic strategies? A ray of hope in the midst of the pandemic. Eur. J. Pharmacol. 887, 173561 (2020).
Wang, Y. et al. Uric acid enhances the antitumor immunity of dendritic cell-based vaccine. Sci. Rep. 5, 16427 (2015).
Man-man, C. & Ling-hua, M. The double faced role of xanthine oxidoreductase in cancer. Acta Pharmacol. Sin. 43, 1623–1632 (2022).
Veiras, L. C. et al. Tubular IL-1β induces salt sensitivity in diabetes by activating renal macrophages. Circ. Res. 131, 59–73 (2022).
Haryono, A., Nugrahaningsih, D. A. A., Sari, D. C. R., Romi, M. M. & Arfian, N. Reduction of serum uric acid associated with attenuation of renal injury, inflammation and macrophages M1/M2 ratio in hyperuricemic mice model. Kobe J. Med. Sci. 64, e107–e114 (2018).
Ghiringhelli, F. et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors. Nat. Med. 15, 1170–1178 (2009).
Deets, K. A. & Vance, R. E. Inflammasomes and adaptive immune responses. Nat. Immunol. 22, 412–422 (2021).
Hu, X. et al. Biodegradation-mediated enzymatic activity-tunable molybdenum oxide nanourchins for tumor-specific cascade catalytic therapy. J. Am. Chem. Soc. 142, 1636–1644 (2020).
Coquet, R. & Willock, D. J. The (010) surface of α-MoO3, a DFT + U study. Phys. Chem. Chem. Phys. 7, 3819–3828 (2005).
Kim, H.-S. et al. Oxygen vacancies enhance pseudocapacitive charge storage properties of MoO3−x. Nat. Mater. 16, 454–460 (2017).
Ravel, B. & Newville, M. ATHENA, ARTEMIS, HEPHAESTUS: data analysis for X-ray absorption spectroscopy using IFEFFIT. J. Synchrotron Radiat. 12, 537–541 (2005).
Qiao, W. et al. Construction of active orbital via single-atom cobalt anchoring on the surface of 1T-MoS2 basal plane toward efficient hydrogen evolution. ACS Appl. Energy Mater. 3, 2315–2322 (2020).
Dong, C. et al. Singlet oxygen triggered by robust bimetallic MoFe/TiO2 nanospheres of highly efficacy in solar-light-driven peroxymonosulfate activation for organic pollutants removal. Appl. Catal. B 286, 119930 (2021).
Du, Y. et al. Computational exploration of reactive fragment for mechanism-based inhibition of xanthine oxidase. J. Organomet. Chem. 864, 58–67 (2018).
Martinon, F., Pétrilli, V., Mayor, A., Tardivel, A. & Tschopp, J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440, 237–241 (2006).
Fan, D. et al. Nanomedicine in cancer therapy. Signal Transduct. Target. Ther. 8, 293 (2023).
Wang, Q. et al. Dynamically switchable magnetic resonance imaging contrast agents. Exploration 1, 20210009 (2021).
Long, E. R. The purines and purine metabolism of some tumors in domestic animals. J. Exp. Med. 18, 512–526 (1913).
Xu, H. et al. Xanthine oxidase-mediated oxidative stress promotes cancer cell-specific apoptosis. Free Radic. Bio. Med. 139, 70–79 (2019).
Finger, E. C. et al. Hypoxic induction of AKAP12 variant 2 shifts PKA-mediated protein phosphorylation to enhance migration and metastasis of melanoma cells. Proc. Natl Acad. Sci. USA 112, 4441–4446 (2015).
Garris, C. S. et al. Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12. Immunity 49, 1148–1161.e7 (2018).
Zhang, Z. et al. Gasdermin E suppresses tumour growth by activating anti-tumour immunity. Nature 579, 415–420 (2020).
Gong, N., Sheppard, N. C., Billingsley, M. M., June, C. H. & Mitchell, M. J. Nanomaterials for T-cell cancer immunotherapy. Nat. Nanotechnol. 16, 25–36 (2021).
Yamaguchi, H., Hsu, J.-M., Yang, W.-H. & Hung, M.-C. Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics. Nat. Rev. Clin. Oncol. 19, 287–305 (2022).
Liu, Y. et al. Intrapleural nano-immunotherapy promotes innate and adaptive immune responses to enhance anti-PD-L1 therapy for malignant pleural effusion. Nat. Nanotechnol. 17, 206–216 (2022).
Kao, K.-C., Vilbois, S., Tsai, C.-H. & Ho, P.-C. Metabolic communication in the tumour–immune microenvironment. Nat. Cell Biol. 24, 1574–1583 (2022).
Propper, D. J. & Balkwill, F. R. Harnessing cytokines and chemokines for cancer therapy. Nat. Rev. Clin. Oncol. 19, 237–253 (2022).
Huang, A. C. & Zappasodi, R. A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance. Nat. Immunol. 23, 660–670 (2022).
Wang, Y. et al. Metabolic modulation of immune checkpoints and novel therapeutic strategies in cancer. Semin. Cancer Biol. 86, 542–565 (2022).
Oaks, Z. et al. Cytosolic aldose metabolism contributes to progression from cirrhosis to hepatocarcinogenesis. Nat. Metabol. 5, 41–60 (2023).
Luzzatto, L., Ally, M. & Notaro, R. Glucose-6-phosphate dehydrogenase deficiency. Blood 136, 1225–1240 (2020).
Chen, J. et al. SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin. Nature 544, 493–497 (2017).
van Unen, V. et al. Visual analysis of mass cytometry data by hierarchical stochastic neighbour embedding reveals rare cell types. Nat. Commun. 8, 1740 (2017).
Du, J. et al. Selective oxidative protection leads to tissue topological changes orchestrated by macrophage during ulcerative colitis. Nat. Commun. 14, 3675 (2023).
Palmer, A. et al. FDR-controlled metabolite annotation for high-resolution imaging mass spectrometry. Nat. Methods 14, 57–60 (2017).
Wang, G. et al. Analyzing cell-type-specific dynamics of metabolism in kidney repair. Nat. Metab. 4, 1109–1118 (2022).
Acknowledgements
We acknowledge financial support from the National Key Research and Development Program of China (2022YFB3203801 and 2022YFB3203800 to D.L.; 2022YFB3203804 and 2023YFF0724101 to F.L.), National Natural Science Foundation of China (32071374 to F.L.), Leading Talent of ‘Ten Thousand Plan’-National High-Level Talents Special Support Plan (to D.L.), Anzhong Scholars Outstanding Talents Plan (to X.H.), Shanghai Municipal Health Commission Traditional Chinese Medicine Research Project (2024PT009 to D.L.), Program of Shanghai Academic Research Leader under the Science and Technology Innovation Action Plan (21XD1422100 to D.L.), Explorer Program of Science and Technology Commission of Shanghai Municipality (22TS1400700 to D.L.), Zhejiang Provincial Natural Science Foundation of China (LR22C100001 to F.L.) and the innovative research team of high-level local universities in Shanghai (SHSMU-ZDCX20210900 to D.L.). We thank the beamline BL14W1 of the Shanghai Synchrotron Radiation Facility (SSRF, China) for providing the beamtime. We thank Z. Wu from the Center of Electron Microscopy at Zhejiang University for help with TEM and energy-dispersive spectroscopy measurements. We thank Shanghai Luming Biological Technology for the AFADESI spatially resolved metabolomics used in this study.
Author information
Authors and Affiliations
Contributions
D.L. and F.L. conceived and designed the project. X.H. designed the experiments. X.H., B.Z., M.Z., W.L., B.H., Z.M., J.S., T.L., S.Y., Z.L. and J.Z. performed the experiments and analysed the data. X.H. drafted the manuscript. D.L., F.L. and C.F. provided constructive advice for data analysis and manuscript writing. All authors reviewed and/or revised the paper.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Peer review
Peer review information
Nature Nanotechnology thanks Thanh Loc Nguyen and Shiren Wang for their contribution to the peer review of this work.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Extended data
Extended Data Fig. 1 FeMoO4 metabzyme promotes the phagocytosis of tumour cells by macrophage.
a, CLSM images of B16 cells after incubation with FITC-FeMoO4 metabzyme. Scale bar, 100 μm. The experiment was repeated three times. b,c, Cell viabilities of B16 cells (b) and RAW264.7 cells (c) after incubation with FeMoO4 metabzyme. All data are presented as means ± s.e.m., n = 3 independent experiments. d, Representative images of RAW264.7 cells after incubation with FeMoO4 metabzyme-treated B16-GFP cells. Scale bar, 10 μm. Green, B16-GFP cells. Red arrow, phagocytosis of B16-GFP cells by macrophage. The experiment was repeated three times.
Extended Data Fig. 2 FeMoO4 metabzyme-mediated tumour cell-specific metabolism regulation.
a, In vivo T2-weighted MR images of B16 melanoma-bearing mouse. Tumour regions are marked with white dashed lines. The experiment was repeated three times. b, Biodistribution of FeMoO4 metabzyme in B16 melanoma-bearing mouse after i.v. administration. c-e, The UA levels of tumours (c), para-carcinoma muscle tissues (d) and serum (e) after different treatments. f, Schematic illustration of tumour-cell-specific metabolic modulation. Data are presented as means ± s.e.m. in (b-e), n = 3 independent experiments. Statistical analysis was performed by one-way ANOVA for comparison in (b-e).
Extended Data Fig. 3 FeMoO4 metabzyme boosts anti-tumor cellular responses.
a-c, The percentage of CD4+ T cells (a), NK cells (b), MDSCs (c) of tumour tissues after different treatments by mass cytometry. d-f, The relative proportion of DCs (d), CD8+ T cells (e) and CD4+ T cells (f) in the tumour-draining lymph nodes. All data are presented as means ± s.e.m., n = 3 independent experiments. Statistical analysis was performed by unpaired t-test (two tailed) for comparison in (a-f). g, Staining pictures of tumour tissues. Scale bar, 50 μm. h, HE staining images of main organs. Scale bar, 100 μm. The experiment was repeated three times. i, Pattern diagram of FeMoO4 metabzyme-mediated cancer metabolic therapy. Upon reaching tumour cells marked by elevated xanthine substrates, FeMoO4 metabzyme catalyses the metabolic-level conversion of xanthine into UA, as a “attack me” signal, facilitating direct communication with macrophages for proinflammatory M1 phenotype polarization. Meanwhile, UA and proinflammatory cytokines could be generated by macrophages to induce DC maturation, thus eliciting antigen-specific T cell activation to directly recognize and attack tumour cells.
Supplementary information
Supplementary Information
Supplementary Figs. 1–26, Table 1, discussion and experimental procedures.
Supplementary Data 1
Source data for the Supplementary Figures.
Source data
Source Data Fig. 2
Statistical source data.
Source Data Fig. 3
Statistical source data.
Source Data Fig. 4
Statistical source data.
Source Data Fig. 5
Statistical source data.
Source Data Fig. 6
Statistical source data.
Source Data Extended Data Figs. 1–3
Statistical source data.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Hu, X., Zhang, B., Zhang, M. et al. An artificial metabzyme for tumour-cell-specific metabolic therapy. Nat. Nanotechnol. 19, 1712–1722 (2024). https://doi.org/10.1038/s41565-024-01733-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41565-024-01733-y
This article is cited by
-
Metabolomic profiling of childhood medulloblastoma: contributions and relevance to diagnosis and molecular subtyping
Journal of Cancer Research and Clinical Oncology (2024)